AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology

Recruitingn/aAges 14 Years - 100 YearsAllShen Chun-Hong
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage. It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients have a diagnosis of new-onset focal epileptic seizure or epilepsy and present with their first seizure within the previous 12 months * Patients are prospectively recruited from the routine practice of epileptologists in epilepsy centers and epilepsy clinics * There is no obvious suspicion of autoimmune encephalitis * Written informed consent and sera are obtained * Cerebrospinal fluid test must be conducted, when patients have detectable serum autoantibodies Exclusion Criteria: * Patients have other etiology of seizures, such as structure, infection, genetics and metabolism. * Written informed consent are not obtained * Loss of follow-up
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy